A detailed history of Advisor Group Holdings, Inc. transactions in Compass Pathways PLC stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 2,978 shares of CMPS stock, worth $25,432. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,978
Previous 2,918 2.06%
Holding current value
$25,432
Previous $24,000 4.17%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
N/A
60 Added 2.06%
2,978 $25,000
Q2 2024

Aug 13, 2024

BUY
N/A
1,111 Added 61.48%
2,918 $24,000
Q1 2024

May 10, 2024

BUY
N/A
65 Added 3.73%
1,807 $15,000
Q4 2023

Feb 12, 2024

SELL
N/A
-5,704 Reduced 76.6%
1,742 $14,000
Q3 2023

Nov 13, 2023

BUY
N/A
1,683 Added 29.2%
7,446 $63,000
Q2 2023

Aug 10, 2023

BUY
$7.79 - $10.69 $3,544 - $4,863
455 Added 8.57%
5,763 $49,000
Q1 2023

May 12, 2023

SELL
$7.32 - $10.85 $717 - $1,063
-98 Reduced 1.81%
5,308 $52,000
Q4 2022

Feb 10, 2023

BUY
$7.84 - $11.68 $23,927 - $35,647
3,052 Added 129.65%
5,406 $43,000
Q3 2022

Nov 14, 2022

BUY
$10.73 - $20.07 $6,008 - $11,239
560 Added 31.22%
2,354 $25,000
Q2 2022

Aug 10, 2022

BUY
$6.76 - $14.18 $1,690 - $3,545
250 Added 16.19%
1,794 $19,000
Q1 2022

May 04, 2022

BUY
$11.13 - $23.04 $411 - $852
37 Added 2.46%
1,544 $316,000
Q3 2021

Nov 05, 2021

BUY
$29.03 - $38.62 $6,502 - $8,650
224 Added 17.46%
1,507 $45,000
Q2 2021

Aug 02, 2021

BUY
$32.29 - $39.68 $18,825 - $23,133
583 Added 83.29%
1,283 $48,000
Q1 2021

May 13, 2021

BUY
$34.75 - $57.5 $5,455 - $9,027
157 Added 28.91%
700 $27,000
Q4 2020

Feb 10, 2021

BUY
$32.0 - $59.2 $4,576 - $8,465
143 Added 35.75%
543 $27,000
Q3 2020

Nov 12, 2020

BUY
$28.83 - $43.17 $11,532 - $17,268
400 New
400 $14,000

Others Institutions Holding CMPS

About COMPASS Pathways plc


  • Ticker CMPS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Care Facilities
  • Shares Outstandng 42,522,400
  • Market Cap $363M
  • Description
  • COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...
More about CMPS
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.